Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy; Khanna, Vishesh; Savage, Samantha L; Rofelty, Angela; English, Isabel; Ho, Hibery; Pandya, Ravi; Bolosky, William J; Poon, Hoifung; Deininger, Michael W; Collins, Robert; Swords, Ronan T; Watts, Justin; Pollyea, Daniel A; Medeiros, Bruno C; Traer, Elie; Tognon, Cristina E; Mori, Motomi; Druker, Brian J; Tyner, Jeffrey W.
Proc Natl Acad Sci U S A
; 114(36): E7554-E7563, 2017 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-28784769
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Checkpoint inhibition in pediatric hematologic malignancies.
Acute myeloid leukemia--major progress over four decades and glimpses into the future.
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
DNA Methyltransferases Demonstrate Reduced Activity against Arabinosylcytosine: Implications for Epigenetic Instability in Acute Myeloid Leukemia.
Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase.
Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance.